Patents by Inventor Caroline Lemarchand

Caroline Lemarchand has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11266614
    Abstract: The present application concerns new formulations of belinostat suitable for oral administration, their process of preparation, the pharmaceutical compositions comprising said formulations and their uses thereof.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: March 8, 2022
    Assignee: ONXEO
    Inventors: Perrine Pivette, Caroline Lemarchand, Ian Yates, Corey Bloom
  • Publication number: 20200155485
    Abstract: The present application concerns new formulations of belinostat suitable for oral administration, their process of preparation, the pharmaceutical compositions comprising said formulations and their uses thereof.
    Type: Application
    Filed: June 29, 2018
    Publication date: May 21, 2020
    Inventors: Perrine PIVETTE, Caroline LEMARCHAND, Ian YATES, Corey BLOOM
  • Patent number: 9192599
    Abstract: The present invention concerns a pharmaceutical composition comprising an alpha-2 adrenergic receptor agonist for preventing or treating inflammatory pain and diseases in mucosa of oral cavity, pharynx and larynx. In another aspect the present invention provides mucosal bioadhesive slow release carriers for the extended and controlled release of alpha-2 adrenergic receptor agonists that can be used on mucosal surfaces for preventing or treating inflammatory pain and diseases in mucosa of oral cavity.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: November 24, 2015
    Assignee: Onxeo S.A.
    Inventors: Pierre Attali, Caroline Lemarchand, Vanessa Roulet, Claire Scheuir, Lorraine Zakin
  • Patent number: 9089559
    Abstract: The present invention concerns a pharmaceutical composition comprising an alpha-2 adrenergic receptor agonist for preventing or treating inflammatory pain and diseases in mucosa of oral cavity, pharynx and larynx. In another aspect the present invention provides mucosal bioadhesive slow release carriers for the extended and controlled release of alpha-2 adrenergic receptor agonists that can be used on mucosal surfaces for preventing or treating inflammatory pain and diseases in mucosa of oral cavity.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: July 28, 2015
    Assignee: ONXEO S.A.
    Inventors: Pierre Attali, Caroline Lemarchand, Vanessa Roulet, Claire Scheuir, Lorraine Zakin
  • Publication number: 20150148398
    Abstract: The present invention concerns a pharmaceutical composition comprising an alpha-2 adrenergic receptor agonist for preventing or treating inflammatory pain and diseases in mucosa of oral cavity, pharynx and larynx. In another aspect the present invention provides mucosal bioadhesive slow release carriers for the extended and controlled release of alpha-2 adrenergic receptor agonists that can be used on mucosal surfaces for preventing or treating inflammatory pain and diseases in mucosa of oral cavity.
    Type: Application
    Filed: February 2, 2015
    Publication date: May 28, 2015
    Inventors: Pierre ATTALI, Caroline LEMARCHAND, Vanessa ROULET, Claire SCHEUIR, Lorraine ZAKIN
  • Patent number: 8791127
    Abstract: A mucosal bioadhesive slow release carrier comprising an active principle and devoid of starch, lactose, which can release the active principal for a duration of longer than 20 hours. This bioadhesive carrier contains a diluent, an alkali metal alkylsulfate, a binding agent, at least one bioadhesive polymer and at least one sustained release polymer, as well as a method for its preparation.
    Type: Grant
    Filed: July 16, 2013
    Date of Patent: July 29, 2014
    Assignee: BioAlliance Pharma
    Inventors: Dominique Costantini, Caroline Lemarchand
  • Patent number: 8747896
    Abstract: A mucosal bioadhesive slow release carrier comprising an active principle and devoid of starch, lactose, which can release the active principal for a duration of longer than 20 hours. This bioadhesive carrier contains a diluent, an alkali metal alkylsulfate, a binding agent, at least one bioadhesive polymer and at least one sustained release polymer, as well as a method for its preparation.
    Type: Grant
    Filed: August 2, 2012
    Date of Patent: June 10, 2014
    Assignee: BioAlliance Pharma
    Inventors: Dominique Costantini, Caroline Lemarchand
  • Patent number: 8592434
    Abstract: The present invention relates to the treatment or prevention of mucocutaneous herpes simplex virus diseases using prolonged release mucoadhesive buccal tablets comprising an acyclic guanosine antiviral agent. These tablets are particularly suitable for the treatment or prevention of orofacial herpes.
    Type: Grant
    Filed: December 9, 2009
    Date of Patent: November 26, 2013
    Assignee: BioAlliance Pharma SA
    Inventors: Pierre Attali, Dominique Costantini, Caroline Lemarchand
  • Publication number: 20130303556
    Abstract: A mucosal bioadhesive slow release carrier comprising an active principle and devoid of starch, lactose, which can release the active principal for a duration of longer than 20 hours. This bioadhesive carrier contains a diluent, an alkali metal alkylsulfate, a binding agent, at least one bioadhesive polymer and at least one sustained release polymer, as well as a method for its preparation.
    Type: Application
    Filed: July 16, 2013
    Publication date: November 14, 2013
    Applicant: BioAlliance Pharma, S.A.
    Inventors: Dominique Costantini, Caroline Lemarchand
  • Publication number: 20130274306
    Abstract: The present invention concerns a pharmaceutical composition comprising an alpha-2 adrenergic receptor agonist for preventing or treating inflammatory pain and diseases in mucosa of oral cavity, pharynx and larynx. In another aspect the present invention provides mucosal bioadhesive slow release carriers for the extended and controlled release of alpha-2 adrenergic receptor agonists that can be used on mucosal surfaces for preventing or treating inflammatory pain and diseases in mucosa of oral cavity.
    Type: Application
    Filed: May 22, 2013
    Publication date: October 17, 2013
    Inventors: Pierre ATTALI, Caroline LEMARCHAND, Vanessa ROULET, Claire SCHEUIR, Lorraine ZAKIN
  • Publication number: 20130210841
    Abstract: The present invention relates to the treatment and/or prevention of muco-cutaneous herpes simplex virus diseases using prolonged release mucoadhesive buccal tablets comprising an acyclic guanosine antiviral agent. These tablets are particularly-suitable for the treatment and/or prevention of orofacial herpes.
    Type: Application
    Filed: December 9, 2010
    Publication date: August 15, 2013
    Inventors: Pierre Attali, Dominique Costantini, Caroline Lemarchand
  • Publication number: 20120326350
    Abstract: A mucosal bioadhesive slow release carrier comprising an active principle and devoid of starch, lactose, which can release the active principal for a duration of longer than 20 hours. This bioadhesive carrier contains a diluent, an alkali metal alkylsulfate, a binding agent, at least one bioadhesive polymer and at least one sustained release polymer, as well as a method for its preparation.
    Type: Application
    Filed: June 29, 2012
    Publication date: December 27, 2012
    Applicant: BIOALLIANCE PHARMA
    Inventors: Dominique COSTANTINI, Caroline LEMARCHAND
  • Publication number: 20120329817
    Abstract: A mucosal bioadhesive slow release carrier comprising an active principle and devoid of starch, lactose, which can release the active principal for a duration of longer than 20 hours. This bioadhesive carrier contains a diluent, an alkali metal alkylsulfate, a binding agent, at least one bioadhesive polymer and at least one sustained release polymer, as well as a method for its preparation.
    Type: Application
    Filed: August 2, 2012
    Publication date: December 27, 2012
    Applicant: Bioalliance Pharma
    Inventors: Dominique COSTANTINI, Caroline Lemarchand
  • Patent number: 8211466
    Abstract: A mucosal bioadhesive slow release carrier comprising an active principle and devoid of starch, lactose, which can release the active principal for a duration of longer than 20 hours. This bioadhesive carrier contains a diluent, an alkali metal alkylsulfate, a binding agent, at least one bioadhesive polymer and at least one sustained release polymer, as well as a method for its preparation.
    Type: Grant
    Filed: February 17, 2010
    Date of Patent: July 3, 2012
    Assignee: Bioalliance Pharma
    Inventors: Dominique Costantini, Caroline Lemarchand
  • Publication number: 20110288140
    Abstract: The present invention concerns a pharmaceutical composition comprising an alpha-2 adrenergic receptor agonist for preventing or treating inflammatory pain and diseases in mucosa of oral cavity, pharynx and larynx. Inanother aspect the present invention provides mucosal bioadhesive slow release carriers for the extended and controlled release of alpha-2 adrenergic receptor agonists that can be used on mucosal surfaces for preventing or treating inflammatory pain and diseases in mucosa of oral cavity.
    Type: Application
    Filed: September 17, 2009
    Publication date: November 24, 2011
    Applicant: BIOALLIANCE PHARMA ,S.A.
    Inventors: Pierre Attali, Caroline Lemarchand, Vanessa Roulet, Claire Scheuir, Lorraine Zakin
  • Publication number: 20100266667
    Abstract: A mucosal bioadhesive slow release carrier comprising an active principle and devoid of starch, lactose, which can release the active principal for a duration of longer than 20 hours. This bioadhesive carrier contains a diluent, an alkali metal alkylsulfate, a binding agent, at least one bioadhesive polymer and at least one sustained release polymer, as well as a method for its preparation.
    Type: Application
    Filed: February 17, 2010
    Publication date: October 21, 2010
    Inventors: Dominique Costantini, Caroline Lemarchand
  • Publication number: 20100087454
    Abstract: A mucosal bioadhesive slow release carrier comprising an active principle, which can release the active principal for a duration of longer than 20 hours. This bioadhesive carrier contains at least one bioadhesive natural protein of vegetal origin and preferably a pea protein from the genus Pisum or the species Pisum sativum, and at least one sustained release polymer, as well as a method for its preparation.
    Type: Application
    Filed: March 21, 2008
    Publication date: April 8, 2010
    Applicant: BIOALLIANCE PHARMA
    Inventor: Caroline Lemarchand
  • Publication number: 20090169511
    Abstract: A mucosal bioadhesive slow release carrier comprising an active principle and devoid of starch, lactose, which can release the active principal for a duration of longer than 20 hours. This bioadhesive carrier contains a diluent, an alkali metal alkylsulfate, a binding agent, at least one bioadhesive polymer and at least one sustained release polymer, as well as a method for its preparation.
    Type: Application
    Filed: March 23, 2007
    Publication date: July 2, 2009
    Applicant: BIOALLIANCE PHARMA
    Inventors: Dominique Costantini, Caroline Lemarchand